Skip to content
Screener

Interest Income at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$4M+33.3%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$6.05M+58.1%
Schering-Plough logo
Schering-PloughSGP
$1.59M+1,163%
TTR
Turn Therapeutics Inc.TTRX
$49.68K+862%
PTH
Pelthos TherapeuticsPTHS
$1.25K-98.8%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$678K-33.9%

Segments

By segment

See full
Reportable Segment$3.7M-12.6%

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.87B+63.9%
Enterprise value$2.75B+59.6%
P/S4.7×-1.2×

Profitability

See full
Gross margin79.8%
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeOther.

The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:25 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001819790-26-000064
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total operating expenses193,820124,844361,996229,459
Loss from operations before other income (expense)(19,908)(22,184)(26,030)(48,464)
Other income (expense):
Interest income3,6984,2297,4207,683
Interest expense(2,156)(2,240)(4,284)(4,453)
Gain on exchange of long-term investments2,8122,812
Other income (expense), net(281)(145)(368)(226)
Total other income (expense), net4,0731,8445,5803,004

Item 1. Financial Statements

FAQ

What is Tarsus Pharmaceuticals, Inc.'s interest income?
Tarsus Pharmaceuticals, Inc. (TARS) reported interest income of $3.7M in Q2 2026.
How has Tarsus Pharmaceuticals, Inc.'s interest income changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s interest income decreased by 12.6% year-over-year, from $4.23M to $3.7M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s interest income?
Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s interest income has grown at a 65.3% compound annual growth rate (CAGR), from $3.49M to $15.75M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Tarsus Pharmaceuticals, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude